Brazil Diabetes Devices Market Size, Share and Forecast Trends - Growth Analysis and Outlook Report 2026-2030

Brazil represents the largest single-country market for diabetes devices in Latin America, supported by one of the region's highest absolute populations of people with diabetes. The market is estimated at approximately USD 1.16 billion in 2025, with a forecast compound annual growth rate near 5.37% through the early 2030s. No Brazilian government agency publishes official commercial market sizing, so figures are produced by private research firms and vary within a narrow band around USD 1.1-1.2 billion for 2025.

• •Market value in 2025 is about USD 1.16 billion, with a CAGR of roughly 5.37%.
• •Brazil accounts for the largest share of the Latin America diabetes devices market.
• •Device categories include BGMs, CGMs, insulin pumps, test strips, and lancets.

Diabetes prevalence in Brazil has been rising steadily due to urbanization, aging, and increasing rates of obesity and sedentary lifestyles, expanding the addressable patient pool. Public health programs and private health plans have progressively broadened reimbursement for self-monitoring supplies, while the SUS (Sistema Único de Saúde) has expanded access to insulin and certain devices for lower-income patients. Newer technologies, especially CGMs, are replacing traditional finger-stick testing and supporting higher per-patient spending.

• •Rising diabetes prevalence and an aging population are expanding the patient base.
• •Expanding reimbursement through private health plans and the public SUS is increasing device uptake.
• •Shift toward CGMs and smart insulin pumps is lifting average revenue per patient.

By product, blood glucose monitoring devices and consumables (meters, strips, lancets) make up the largest share of revenue today, while CGMs represent the fastest-growing segment as prices gradually come down. Insulin delivery devices, including pumps and pen needles, form a smaller but steadily expanding category. Geographically, the Southeast region, led by São Paulo and Rio de Janeiro, accounts for the largest share of sales due to population density, higher per-capita income, and concentration of private healthcare providers; the South and Northeast are growing faster from a smaller base.

• •BGMs and consumables dominate revenue; CGMs are the fastest-growing product segment.
• •The Southeast region leads demand, with the South and Northeast growing quickly.
• •Urban centers drive adoption due to greater private health plan penetration and specialist availability.

What are the recent trends and outlook?

CGM adoption among people with Type 1 and increasingly Type 2 diabetes is expected to be the single most important driver of value growth over the next decade. Connected devices, smartphone-paired apps, and integration with insulin pumps are supporting a transition toward more automated diabetes management. The long-term outlook remains positive, with continued mid-single-digit annual growth expected as reimbursement expands and device prices gradually become more affordable for the wider Brazilian population.

• •CGM penetration is the leading growth catalyst, with potential reimbursement expansion under SUS.
• •Digital health integration (apps, telehealth, data-sharing with clinicians) is accelerating.
• •Mid-single-digit annual growth is expected to continue through the early 2030s.